no more semaglutide A stronger 7.2 mg dose of Wegovy wins FDA approval after a 54-day review, promising greater weight loss for eligible patients. || FULL STORY IN COMMENTS 💊 Exciting news! Wegovy (semaglutide)

GLP-1 drugs primarily support glucose control and weight loss, while SGLT2 inhibitors offer strong heart and kidney protection

"Semaglutide is here to stay," said Agarwal, emphasising that it is seen by doctors as a 'statin moment' in diabetes and obesity category, referring to the mass use of the cholesterol-buster for heart patients

If you are planning to start semaglutide treatment, you can expect the following results with semaglutide: Remember, the individual response to the weight loss treatment may be different depending on various factors such as metabolic health, body mass index, lifestyle, and presence of comorbidities

Reassessing your nutrition pattern, meal timing, and protein intake can re-sensitize your GLP-1 response without changing drugs